ReviewFrontiers in oncology2025
CircRNAs in colorectal cancer: potential roles, clinical applications, and natural product-based regulation.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- CSDPCDA: A miRNA-Mediated Cross-Semantic Regulatory Network Framework for Predicting circRNA-Disease Associations.International journal of molecular sciences · 2026Article
- Multi Omics Integration in Colorectal Cancer: From Molecular Insights to Precision Oncology.Cancers · 2026Review
- Target, silence, replace: a review on RNA-based drugs in modern medicine.Frontiers in cell and developmental biology · 2026Review
- Molecular profiling and bioinformatics validation of CEACAM6, HOXA-AS3 and miR29a in colorectal cancer.Scientific reports · 2025Article
- Overexpression of CircularInternational journal of molecular sciences · 2025Article
- Unveiling Pharmacogenomics Insights into Circular RNAs: Toward Precision Medicine in Cancer Therapy.Biomolecules · 2025Review
- A review of circular RNAs in colorectal cancer: insights into biomarker discovery and therapeutic targeting.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide. In recent years, circular RNAs (circRNAs), a novel class of non-coding RNA molecules, have emerged as a research focus due to their unique stability and functional roles. CircRNAs regulate tumor-related signaling pathways through interactions with microRNAs (miRNAs) and proteins, playing key roles in tumorigenesis, progression, invasion, metastasis, and chemoresistance. This review summarizes the role of circRNAs in CRC, particularly their mechanisms in cell proliferation, migration, apoptosis, tumor microenvironment (TME) remodeling, and immune evasion. Aberrant expression of circRNAs holds great potential as diagnostic and prognostic biomarkers as well as therapeutic targets for CRC. Additionally, natural products such as flavonoids and glycosides, by modulating circRNA-miRNA-mRNA networks, offer promising therapeutic strategies. The article also discusses the current technical challenges in circRNA research and its future application prospects in CRC, highlighting the need for further investigation into the role of circRNAs in tumor immune microenvironments and drug resistance mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.